Business Details
Your Trusted Partner for Pharmaceutical Solutions
Upsher-Smith Laboratories is dedicated to developing and manufacturing high-quality medications that enhance patient health outcomes. With a focus on cost-effective therapies for U.S. patients, we have expanded our capabilities through strategic mergers with Pyros Pharmaceuticals and TWi Pharmaceuticals, integrating innovative treatments and specialized R&D expertise into our portfolio. Our commitment to advancing patient care is reflected in our diverse product range, including brand medications for migraines and seizure disorders, as well as a comprehensive selection of generic pharmaceuticals.We prioritize employee development and operational excellence, offering career opportunities across quality assurance, technical services, regulatory affairs, and more. Recent product launches, such as Difluprednate Ophthalmic Emulsion 0.05%, underscore our dedication to addressing unmet medical needs. By combining domestic and global partnerships, we aim to deliver high-quality healthcare solutions across increasingly diverse dosage forms, ensuring accessibility and reliability for patients and healthcare providers alike.
Services
Brand Medications
Generic Pharmaceuticals
Strategic Mergers
R&D Collaborations
Product Development
Highlights and features
- We integrate Pyros Pharmaceuticals' treatments into our portfolio for enhanced patient care.
- Our merger with TWi Pharmaceuticals strengthens R&D capabilities and product development.
- We offer diverse career opportunities with a focus on employee growth and benefits.
- Recent product launches demonstrate our commitment to addressing unmet medical needs.
- Strategic partnerships expand our ability to deliver cost-effective therapies nationwide.
Services
Brand Medications
We develop and manufacture brand medications targeting migraine headaches and seizure disorders. Our formulations prioritize efficacy and safety, addressing critical patient needs through rigorous quality standards. These treatments reflect our commitment to innovation in neurological health management.
Generic Pharmaceuticals
Our generic medication portfolio offers affordable alternatives to branded drugs without compromising quality. By expanding our generics production, we help reduce healthcare costs while maintaining strict compliance with regulatory requirements for bioequivalence and manufacturing excellence.
Strategic Mergers
Through acquisitions like Pyros Pharmaceuticals and TWi Pharmaceuticals, we've enhanced our treatment offerings and R&D capabilities. These strategic integrations allow us to combine specialized expertise with our existing infrastructure to accelerate product development and market reach.
Product Development
Our product development pipeline focuses on diverse dosage forms and novel treatments. Recent launches like Difluprednate Ophthalmic Emulsion demonstrate our ability to bring innovative solutions to market, supported by robust clinical research and manufacturing capabilities.
Employee Development
We invest in comprehensive training programs for our employees across quality control, regulatory affairs, and technical operations. This commitment to professional growth ensures we maintain industry-leading standards while fostering a skilled, motivated workforce.
Questions
What therapeutic areas does Upsher-Smith specialize in?
We focus on neurological conditions including migraines and seizure disorders, with expanding capabilities in ophthalmic and other specialty treatments through recent acquisitions.
How do mergers benefit Upsher-Smith's product offerings?
Our acquisitions of Pyros Pharmaceuticals and TWi Pharmaceuticals have expanded our R&D capabilities and diversified our product portfolio with innovative treatments and specialized expertise.
What career opportunities are available at Upsher-Smith?
We offer positions in quality assurance, regulatory affairs, technical services, R&D, and business operations, with comprehensive benefits and professional development programs.
Where are Upsher-Smith's operations based?
Our primary operations are located in Maple Grove, Minnesota, with strategic partnerships and distribution networks across the United States.
What recent product launches have Upsher-Smith announced?
In September 2025, we launched Difluprednate Ophthalmic Emulsion 0.05%, a ready-to-use solution for ophthalmic treatment applications.
